Divergent Planning LLC Takes Position in Kenvue Inc. $KVUE

Key Points

• Divergent Planning LLC acquired a new position in Kenvue Inc., purchasing 93,497 shares valued at approximately $1,957,000 during the second quarter.
• Kenvue recently reported a quarterly EPS of $0.29, exceeding analysts' estimates, but experienced a 4% decline in revenue compared to the same quarter last year.
• The company declared a quarterly dividend of $0.2075, up from the previous $0.21, resulting in an annualized yield of 5.5%.

Divergent Planning LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 93,497 shares of the company's stock, valued at approximately $1,957,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Kenvue by 33.2% in the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company's stock valued at $594,000 after acquiring an additional 6,169 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Kenvue by 2.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 620,052 shares of the company's stock valued at $14,869,000 after purchasing an additional 16,404 shares during the last quarter. QRG Capital Management Inc. raised its holdings in Kenvue by 54.8% in the first quarter. QRG Capital Management Inc. now owns 15,832 shares of the company's stock worth $380,000 after purchasing an additional 5,607 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Kenvue in the first quarter worth about $1,335,000. Finally, Cambridge Investment Research Advisors Inc. lifted its position in shares of Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after buying an additional 4,034 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE opened at $14.96 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company's fifty day moving average price is $18.42 and its 200-day moving average price is $20.97. Kenvue Inc. has a 1-year low of $14.05 and a 1-year high of $25.17. The firm has a market capitalization of $28.71 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm's revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.5%. Kenvue's dividend payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $24.00 to $21.00 and set an "overweight" rating on the stock in a research report on Friday, October 10th. Rothschild Redb upgraded shares of Kenvue from a "hold" rating to a "strong-buy" rating in a research note on Friday, September 26th. Barclays cut their price target on shares of Kenvue from $20.00 to $17.00 and set an "equal weight" rating on the stock in a report on Wednesday, October 1st. Evercore ISI decreased their price objective on Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a report on Tuesday, September 23rd. Finally, Canaccord Genuity Group lowered their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.